Reading ASPI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ASPI free→Reading ASPI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ASPI free→NASDAQMaterialsChemicalsSnapshot 2026-06-15
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak, and management's recent track record has been unsteady, with frequent disruptive corporate changes. The company was unprofitable over the past year, so its earnings quality can't be assessed, and risk is high. The sector backdrop is a headwind, which could further challenge ASPI. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $6.64. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Materials names rated weak grew net income 51% of the time over the next year (vs 59% for the rest of the cohort, n=1088).
Over the trailing year it converted 0.33x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates.
30 material management or governance events in the past 24 months, led by M&A activity. Historically, Materials names rated volatile grew net income 61% of the time over the next year (vs 51% for the rest of the cohort, n=235).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.27 → $-0.31 (-12.2% / 30d). 0 raised, 1 cut, 3 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
0 positive, 2 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$488.
How much price usually moves either way.
On a bad day, this stock has moved -$1,072.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $7,103.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Positive revenue growth would signal a change in the declining trend of the materials sector. This could improve investor confidence.
Confirms:Revenue growth turns positive after being near -1 percent.
Disproves:Revenue growth remains negative or worsens.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for ASPI yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Regulation FD Disclosure. On May 26, 2026, ASP Isotopes Inc. (the “Company”) issued a press release regarding the Company's production of Silicon-28, which is attached hereto as Exhibit 99.1 (the “Press Release”) and is incorporated by reference herein. In addition, the Company released its latest investor presentation (the “Presentation”). The Presentation is available on the Company’s website, www.aspisotopes.com, on the Home page. All of the information in the Press Release and the Present…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Diversified Chemicals.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
ASPI ASP Isotopes, Inc. | Typical Show detailsSector percentile: 32 of 100 | — | high |
CBT Cabot Corp | Above typical Show detailsSector percentile: 98 of 100 | inexpensive | moderate |
CC Chemours | Below typical Show detailsSector percentile: 11 of 100 | full | high |
ASH Ashland Global | Typical Show detailsSector percentile: 62 of 100 | fair | moderate |
OLN Olin Corporation | Typical Show detailsSector percentile: 62 of 100 | inexpensive | elevated |
Not investment advice. As of 2026-06-15.
via XLB
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
The company plans to begin initial commercial shipments of enriched Silicon-28 in the third quarter of 2026.
Newly stated in 2026-Q1. The company plans to begin initial commercial shipments of enriched Silicon-28 in Q3 2026. Financials show a gross profit of $1.67M in 2026-Q1, indicating limited progress towards this new product milestone.
“The Company expects to make initial commercial shipments of enriched Silicon-28 in Q3 2026.”
The company aims to achieve revenues of $10 million or more from radiopharmacies in 2026, approximately double 2025 reported revenue.
Newly stated in 2026-Q1. The company aims for $10M revenue from radiopharmacies in 2026. Revenue was $4.18M in 2026-Q1, indicating a need for significant growth to meet the target. Progress towards this goal is not yet evident.
Regulation FD Disclosure. On May 20, 2026, ASP Isotopes Inc. (the “Company”) released its latest investor presentation (the “Presentation”). The Presentation is available on the Company’s website, www.aspisotopes.com, on the Home page. All of the information in the Presentation is presented as of the date hereof, and the Company does not assume any obligation to update such information in the future. The information in the Presentation shall not be deemed to be “filed” for purposes of Section…
and in the Press Release shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission, whether made by the Company before or after the date hereof, regardless of any general incorporation language in such filin…
and in the Press Release shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission, whether made by the Company before or after the date hereof, regardless of any general incorporation language in such filin…
and in the Press Release, the Business Update Call Presentation and the Corporate Overview shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission, whether made by the Company before or after the date here…
“The Company targets revenues of $10 million or more from radiopharmacies in 2026.”